PD-1/PD-L1 Inhibitors Response in Triple-Negative Breast Cancer: Can Long Noncoding RNAs Be Associated?

As immune checkpoint inhibitors (ICI) emerge as a paradigm-shifting treatment option for patients with advanced or metastatic cancer, there is growing demand biomarkers that can distinguish which are likely to benefit. In the case of triple-negative breast cancer (TNBC), characterized by lack therapeutic targets, pembrolizumab approval high-risk early-stage disease occurred regardless PD-L1 status, keeps condition in biomarker limbus. this review, we highlight participation long non-coding RNAs (lncRNAs) regulation PD-1/PD-L1 pathway, well definition prognostic immune-related signatures many types tumors, aiming shed light on molecules deserve further investigation potential role biomarkers. We also conducted bioinformatic analysis investigate lncRNAs already investigated PD-1/PDL-1 pathways other types, considering TNBC molecular context. sense, from generated data, evidence here two lncRNAs, UCA1 and HCP5, have not yet been identified context tumoral response cancer. These candidates be explored verify their use ICI response. article, present an updated review regarding lncRNA ICI, highlighting versatility using these molecules.